Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    19692680 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Gefitinib;   Drug: Carboplatin;   Drug: Paclitaxel
2 Not yet recruiting Novel Detection System for Lung Cancer Curative Effect Monitoring
Condition: Lung Neoplasms
Intervention:
3 Active, not recruiting Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Aprepitant and placebo;   Drug: desloratadine and placebo
4 Active, not recruiting Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
Condition: Advanced Non Small Cell Lung Cancer
Intervention:
5 Recruiting Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
Conditions: Non-small Cell Lung Cancer Metastatic;   EGFR Activating Mutation
Interventions: Drug: Gefitinib;   Drug: gemcitabine;   Drug: carboplatin
6 Not yet recruiting Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma
Condition: Lung Cancer
Interventions: Drug: Apatinib;   Drug: Tarceva;   Drug: Placebo
7 Unknown  Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient
Conditions: Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent;   No EGFR Activating Mutation
Interventions: Radiation: 18F-FLT-TEP;   Radiation: 18F-FDG-TEP
8 Unknown  Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC
Condition: Non-small-cell Lung Cancer
Intervention: Drug: Gefitinib
9 Completed Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: neoadjuvant erlotinib therapy;   Drug: neoadjuvant gemcitabine/carboplatin therapy
10 Recruiting Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma
Condition: Adenocarcinoma of Lung (Disorder)
Intervention: Genetic: Sequencing of ctDNA in plasma
11 Recruiting Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MK-3475;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
12 Recruiting Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
Condition: Non-small-cell Lung Cancer
Interventions: Drug: Nimotuzumab;   Drug: docetaxel and cisplatin;   Radiation: daily RT (65Gy in 25 fractions) to the chest;   Drug: placebo
13 Not yet recruiting A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Condition: Lungcancer
Interventions: Drug: Binimetinib;   Drug: Pemetrexed;   Drug: Carboplatin
14 Withdrawn A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Intervention: Drug: BIBW 2992 (Afatinib)
15 Unknown  Tarceva Italian Lung Optimization tRial
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Erlotinib;   Drug: Docetaxel

Study has passed its completion date and status has not been verified in more than two years.